Nothing Special   »   [go: up one dir, main page]

WO2002036818A3 - Method for detecting inhibitors of tumour growth - Google Patents

Method for detecting inhibitors of tumour growth Download PDF

Info

Publication number
WO2002036818A3
WO2002036818A3 PCT/GB2001/004891 GB0104891W WO0236818A3 WO 2002036818 A3 WO2002036818 A3 WO 2002036818A3 GB 0104891 W GB0104891 W GB 0104891W WO 0236818 A3 WO0236818 A3 WO 0236818A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumour growth
detecting inhibitors
inhibitors
detecting
smo
Prior art date
Application number
PCT/GB2001/004891
Other languages
French (fr)
Other versions
WO2002036818A2 (en
Inventor
Veronica Martin
Graciela Carrillo
Isabel Guerrero
Carlos Torroja
Original Assignee
Consejo Superior Investigacion
Ruffles Graham Keith
Veronica Martin
Graciela Carrillo
Isabel Guerrero
Carlos Torroja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior Investigacion, Ruffles Graham Keith, Veronica Martin, Graciela Carrillo, Isabel Guerrero, Carlos Torroja filed Critical Consejo Superior Investigacion
Priority to AU2002212494A priority Critical patent/AU2002212494A1/en
Publication of WO2002036818A2 publication Critical patent/WO2002036818A2/en
Publication of WO2002036818A3 publication Critical patent/WO2002036818A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compounds that block HH signalling through modifications of PTC and SMO vesicular sorting are of use in the preparation of medicaments for the treatment of a mammalian cancer.
PCT/GB2001/004891 2000-11-02 2001-11-02 Method for detecting inhibitors of tumour growth WO2002036818A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002212494A AU2002212494A1 (en) 2000-11-02 2001-11-02 Method for detecting inhibitors of tumour growth

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0026834.2A GB0026834D0 (en) 2000-11-02 2000-11-02 Method for detecting inhibitors of tumour growth
GB0026834.2 2000-11-02

Publications (2)

Publication Number Publication Date
WO2002036818A2 WO2002036818A2 (en) 2002-05-10
WO2002036818A3 true WO2002036818A3 (en) 2003-10-02

Family

ID=9902458

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/004891 WO2002036818A2 (en) 2000-11-02 2001-11-02 Method for detecting inhibitors of tumour growth

Country Status (3)

Country Link
AU (1) AU2002212494A1 (en)
GB (1) GB0026834D0 (en)
WO (1) WO2002036818A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044344A2 (en) * 2000-11-28 2002-06-06 Curis, Inc. Basal cell carcinoma cultures, methods related thereto and their use
WO2006080894A2 (en) * 2005-01-31 2006-08-03 Karolinska Institutet Innovations Ab Hedgehog inhibitor assay
ES2302625B1 (en) * 2006-09-30 2009-05-29 Consejo Sup. De Invest. Cientificas NON-HUMAN ANIMAL MODEL USEFUL FOR THE IDENTIFICATION OF PHARMACEUTICAL COMPOUNDS REGULATING THE VIA HEDGEHOG, PROCEDURE OF OBTAINING AND ITS USE IN A PROCEDURE OF IDENTIFICATION OF PHARMACEUTICAL COMPOUNDS REGULATING THE VIA HEDGEHOG.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019800A2 (en) * 1999-09-16 2001-03-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019800A2 (en) * 1999-09-16 2001-03-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GRACHTCHOUK M ET AL: "Basal cell carcinomas in mice overexpressing Gli2 in skin.", NATURE GENETICS. UNITED STATES MAR 2000, vol. 24, no. 3, March 2000 (2000-03-01), pages 216 - 217, XP002239783, ISSN: 1061-4036 *
HOPYAN SEVAN ET AL: "Indian Hedgehog and Parathyroid hormone related protein signaling in cartilage tumors of bone.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, no. 41, March 2000 (2000-03-01), 91st Annual Meeting of the American Association for Cancer Research.;San Francisco, California, USA; April 01-05, 2000, March, 2000, pages 206, XP002239782, ISSN: 0197-016X *
MURONE MAXIMILIEN ET AL: "Sonic hedgehog signaling by the patched-smoothened receptor complex.", CURRENT BIOLOGY, vol. 9, no. 2, 28 January 1999 (1999-01-28), pages 76 - 84, XP002239781, ISSN: 0960-9822 *
SASAKI HIROSHI ET AL: "A binding site for Gli proteins is essential for HNF-3-beta floor plate enhancer activity in transgenics and can respond to Shh in vitro.", DEVELOPMENT (CAMBRIDGE), vol. 124, no. 7, 1997, pages 1313 - 1322, XP002239784, ISSN: 0950-1991 *
TAIPALE JUSSI ET AL: "Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine.", NATURE (LONDON), vol. 406, no. 6799, 2000, pages 1005 - 1009, XP002239780, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
WO2002036818A2 (en) 2002-05-10
AU2002212494A1 (en) 2002-05-15
GB0026834D0 (en) 2000-12-20

Similar Documents

Publication Publication Date Title
IL161746A0 (en) Closed automated system for tissue based therapy, dosing and administration using same
HK1048813A1 (en) Indazole compounds and pharmaceutical compositionsfor inhibiting protein kinases, and methods for their use.
AU2002339157A1 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
HK1079683A1 (en) Systems and methods for moving and/or restraining tissue in the upper respiratory system
AU6501201A (en) Systems and methods for monitoring health and delivering drugs transdermally
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
SG144712A1 (en) Nordihydroguaiartic derivaties for use in treatment of tumors
EP1436680A4 (en) Precision dosage apparatus, system and method
AUPR839001A0 (en) Dosage form, device and methods of treatment
MX9800408A (en) Cyclo-oxygenase inhibitor and amidine derivative salts, preparation method therefor, use thereof as drugs, and pharmaceutical compositions containing said salts.
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU2001287890A1 (en) Radiotherapy apparatus and collimator set therefor
AU2001255638A1 (en) Systems and methods for dental treatment planning
AU2910397A (en) Cytokine production inhibitors, formulations thereof and their use in medicine, and methods for their identification
AU6225999A (en) Disposable training pant, apparatus and method for manufacturing it
AU2002353246A1 (en) Oral veterinary drug delivery system and/or feed additive delivery system, process for the preparation and use thereof
WO2002036818A3 (en) Method for detecting inhibitors of tumour growth
AU2001238493A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU2002231223A1 (en) Compositions and methods for treating hematologic malignancies and multiple drug resistance
MXPA03006249A (en) 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them and therapeutic use thereof.
AU2002233407A1 (en) 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them and therapeutic use thereof
ZA200007111B (en) Methods and devices for providing prolonged drug therapy.
AU2002231283A1 (en) Use of p38 inhibitors for the treatment of smoke inhalation
WO2002076930A3 (en) Substituted diarylureas as stimulators for fas-mediated apoptosis
AU2001245939A1 (en) Compositions and methods for the identification, assessment, prevention, and therapy of human cancers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP